ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Cancer-related cognitive impairment in patients with hematologic malignancies after CAR T cell therapy: a systematic review and meta-analysis of prevalence.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Pooled it
- Links between nocturnal hypoxia and cognitive function in breast cancer.Scientific reports · 2025Trial
- Quality of Life Among Patients With Ductal Carcinoma In Situ.JAMA network open · 2025Trial
- Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Trial
- Randomized double-masked controlled trial of cognitive training in breast cancer survivors: a preliminary study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Trial
- Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Interaction of endocrine therapy for breast cancer with APOE4 status on cognition over 5-year follow-up.JNCI cancer spectrum · 2026Article
- Factors and pathways Influencing Fertility Anxiety in Reproductive-Age Male Cancer Patients: A Stress Process Theory Perspective.Reproduction & fertility · 2026Article
- Ecological Momentary Assessment for Assessing Affect Patterns Associated With Depression in Cancer Survivors in Primary Care: A Pilot Study.Psycho-oncology · 2026Article
- Cognitive training for breast cancer patients with cancer-related cognitive impairment: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Trajectories and related factors of subjective cognitive function in patients living with breast cancer receiving postoperative chemotherapy: a latent class growth model study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Long-term health-related quality of life among adolescent and young adult breast cancer survivors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Unveiling Cognitive Impairment in Older Adults with Cancer on Systemic Anticancer Therapy: A Comprehensive Review.Drugs & aging · 2025Review
- Expression of inflammatory states in response to psychological distress in breast cancer survivors and its relationship to subjective memory function complaints.BMC women's health · 2025Article
- The National Cancer Institute clinical trials planning meeting to address gaps in observational and intervention trials for cancer-related cognitive impairment.Journal of the National Cancer Institute · 2025Article
- Cancer-Related Cognitive Impairment and the Potential of Dietary Interventions for the Prevention and Mitigation of Neurodegeneration.Cancer research · 2025Review
- Liquid biopsy for breast cancer and other solid tumors: a review of recent advances.Breast cancer (Tokyo, Japan) · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 14 institutions in 2 countries.
Funding
Abstract
purposeCancer-related cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist. TAILORx provided a novel opportunity to prospectively assess patient-reported cognitive impairment among women with early breast cancer who were randomly assigned to chemoendocrine therapy (CT+E) versus endocrine therapy alone (E), allowing us to quantify the unique contribution of chemotherapy to CRCI.
methodsWomen with a 21-gene recurrence score of 11 to 25 enrolled in TAILORX were randomly assigned to CT+E or E. Cognitive impairment was assessed among a subgroup of 552 evaluable women using the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaire, administered at baseline, 3, 6, 12, 24, and 36 months. The FACT-Cog included the 20-item Perceived Cognitive Impairment (PCI) scale, our primary end point. Clinically meaningful changes were defined a priori and linear regression was used to model PCI scores on baseline PCI, treatment, and other factors.
resultsFACT-Cog PCI scores were significantly lower, indicating more impairment, at 3, 6, 12, 24, and 36 months compared with baseline for both groups. The magnitude of PCI change scores was greater for CT+E than E at 3 months, the prespecified primary trial end point, and at 6 months, but not at 12, 24, and 36 months. Tests of an interaction between menopausal status and treatment were nonsignificant.
conclusionAdjuvant CT+E is associated with significantly greater CRCI compared with E at 3 and 6 months. These differences abated over time, with no significant differences observed at 12 months and beyond. These findings indicate that chemotherapy produces early, but not sustained, cognitive impairment relative to E, providing reassurance to patients and clinicians in whom adjuvant chemotherapy is indicated to reduce recurrence risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.